Sistemic and Roslin Cells Ink Stem Cell Standardisation Deal

12-May-2011 - United Kingdom

Sistemic Ltd and Roslin Cells Ltd signed a Memorandum of Understanding to promote the development of new technologies for the standardisation of the manufacture of stem cells for their use in cell therapy and drug development screening. Both parties believe that only through the development of stem cell standardisation can the full potential of this major opportunity be unlocked.

Jim Reid, Sistemic’s CEO commented “Standardisation is a key step in the broader exploitation of any technology. We have been using our SistemQC™ microRNA based service with clients working in these fields to help them gain a greater molecular understanding of their stem cell systems and have built a comprehensive understanding of the issues this sector currently faces. We have been looking both at early characterisation during the R&D phase, right through to generating microRNA fingerprints which can be used in the release of products from manufacture. We have been finding that there is a general consensus within the stem cell community that the currently available tools and technologies are not truly fit for purpose. Broader utility will be driven by better standardisation. As more and more of these developments enter clinical testing and subsequent market launch the role for new tools and technologies to really understand these systems is essential. We believe that our SistemQC™, microRNA approach will play a key part in delivering these enhanced tools and in collaboration with Roslin set the standard for stem cell characterisation and quality.”

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances